At the OncLive National Fellows Forum during SABCS 2025, notable data were presented on ethnic differences in early HR+ breast cancer and genomic insights in women post partum.
Vol.18-No.1
Jill Gilbert, MD, offers a primer for hematology/oncology fellows ahead of the busy 2026 meeting season.
OncLive outlines some of the most notable new agents and combinations to earn FDA approval in 2025, including the topline data supporting these decisions.
Oncology Fellows spotlights fellows who received research fellowship grants during the 2025 ESMO Congress.
The predictive value of PD-L1 expression on response to chemoimmunotherapy was greater on metastatic lesions vs primary tumors in HGSOC.
Advertisement
Advertisement
Trending on OncLive
1
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
2
Imaging Cadence, Radiation Timing, and Osimertinib Dosing Frame CNS Management Decisions in EGFR-Mutated NSCLC
3
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
4
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
5